Immix Biopharma, Inc. (IMMX)
7.48
-0.36
(-4.59%)
USD |
NASDAQ |
Nov 16, 16:00
7.49
+0.01
(+0.13%)
After-Hours: 20:00
Immix Biopharma Shareholders Equity (Quarterly) : 335.06M for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 335.06M |
| June 30, 2026 | 228.92M |
| March 31, 2026 | 84.36M |
| December 31, 2025 | 93.80M |
| September 30, 2025 | 8.265M |
| June 30, 2025 | 4.653M |
| March 31, 2025 | 9.594M |
| December 31, 2024 | 13.25M |
| September 30, 2024 | 17.55M |
| June 30, 2024 | 23.89M |
| March 31, 2024 | 27.92M |
| Date | Value |
|---|---|
| December 31, 2023 | 16.41M |
| September 30, 2023 | 19.77M |
| June 30, 2023 | 13.23M |
| March 31, 2023 | 11.77M |
| December 31, 2022 | 13.16M |
| September 30, 2022 | 16.75M |
| June 30, 2022 | 18.11M |
| March 31, 2022 | 19.65M |
| December 31, 2021 | 17.99M |
| September 30, 2021 | -6.196M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.387B |
| Alnylam Pharmaceuticals, Inc. | 3.604B |
| Anika Therapeutics, Inc. | 137.58M |
| Savara, Inc. | 107.85M |
| Arrowhead Pharmaceuticals, Inc. | 50.31M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 345.95M |
| Total Liabilities (Quarterly) | 10.89M |
| Debt to Equity Ratio | 0.0029 |
| Current Ratio | 33.72 |
| Net Debt Paydown Yield | 0.00% |